Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OrienX010 + toripalimab
- Development stage
- Unknown
- Lead developer
- OrienGene Biotechnology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
OrienX010 + toripalimab is a combination therapy consisting of an oncolytic virus (OrienX010) and an anti-PD-1 monoclonal antibody (toripalimab). OrienX010 appears to be a granulocyte-macrophage colony-stimulating factor-expressing oncolytic virus that directly attacks cancer cells while stimulating immune responses. Toripalimab is a PD-1 inhibitor that blocks PD-1 ligands 1 and 2, preventing the inhibition of T-cell responses against tumors. The combination has shown promising antitumor activity in clinical trials for melanoma, particularly acral melanoma.
- Brand names
- Tuoyi
- Other names
- Recombinant GM-CSF herpes simplex virus + toripalimab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on OrienX010 + toripalimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OrienX010 + toripalimab.